Pluristem (PSTI) Announces Common, Warrants Offering
Tweet Send to a Friend
Pluristem Therapeutics Inc. (Nasdaq: PSTI) intends, subject to market and other conditions, to offer shares of its common stock and warrants to purchase shares of its common stock in a registered public offering. The shares of common stock and warrants to purchase shares of common stock are being offered as units. Pluristem also intends to grant the underwriters of the offering an option to purchase additional shares of common stock and warrants to cover over-allotments, if any. Pluristem plans to use the proceeds from the offering to conduct clinical trials, research and product development activities and for general corporate purposes, including general working capital purposes. Jefferies & Company, Inc. is acting as sole book-running manager for the proposed offering. Oppenheimer & Co. Inc. is acting as co-lead manager for the proposed offering. Needham & Company, LLC and Maxim Group LLC are acting as co-managers for the proposed offering. In addition, Leader Capital Markets Ltd. is acting as the company's financial advisor in connection with the proposed offering.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Pluristem Welcomes Parliamentary State Secretary of the German Federal Ministry for Environmental, Nature Conservation and Nuclear Safety and the Chairman of the Charite Berlin-Brandenburg Center for
- Galena Biopharma (GALE) Registers 10.77M Shares Tied to Warrants
- Blackstone Mortgage (BXMT) Prices Larger 22.5M Common Stock Offering
Create E-mail Alert Related Categories
Equity OfferingsRelated Entities
Jefferies & Co, Needham & Company, Maxim GroupLogin with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

Up)